Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Caliway Biopharmaceuticals Co's PB Ratio or its related term are showing as below:
TPE:6919'
s PB Ratio Range Over the Past 10 Years
Min: 4.8 Med: 17.64 Max: 42.09
Current: 16.03
During the past 7 years, Caliway Biopharmaceuticals Co's highest PB Ratio was 42.09. The lowest was 4.80. And the median was 17.64.
TPE:6919's PB Ratio is ranked worse than 92.02% of 1216
companies
in the Biotechnology industry
Industry Median: 2.925
vs TPE:6919: 16.03
During the past 12 months, Caliway Biopharmaceuticals Co's average Book Value Per Share Growth Rate was -2.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 47.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 124.70% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Caliway Biopharmaceuticals Co was 313.40% per year. The lowest was 47.50% per year. And the median was 82.00% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Caliway Biopharmaceuticals Co PB Ratio Related Terms
Caliway Biopharmaceuticals Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Caliway Biopharmaceuticals Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Caliway Biopharmaceuticals Co PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Caliway Biopharmaceuticals Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Caliway Biopharmaceuticals Co's PB Ratio falls into.
Caliway Biopharmaceuticals Co PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Caliway Biopharmaceuticals Co (TPE:6919) has a PB Ratio of 16.02 as of Aug. 31, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Caliway Biopharmaceuticals Co and its competitors. This is near median its historical median of 17.64. Over the past decade, Caliway Biopharmaceuticals Co's PB Ratio has ranged from 4.80 to 42.09. According to the industry distribution chart, Caliway Biopharmaceuticals Co ranks #1119 out of 1216 companies in the Biotechnology industry, placing it in the top 92%.
Is Caliway Biopharmaceuticals Co's PB Ratio too high?
Caliway Biopharmaceuticals Co's current PB Ratio of 16.02 is near median its 10-year median of 17.64. Over the past 10 years, this metric has ranged from a low of 4.80 to a high of 42.09. The Biotechnology industry median PB Ratio is 2.93. Caliway Biopharmaceuticals Co's value of 16.02 is 447.7% above this industry median. Based on the distribution chart, Caliway Biopharmaceuticals Co ranks #1119 out of 1216 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Caliway Biopharmaceuticals Co has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Caliway Biopharmaceuticals Co's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Caliway Biopharmaceuticals Co ranks #1119 out of 1216 companies for PB Ratio. This places Caliway Biopharmaceuticals Co in the lower half of its industry. The industry median PB Ratio is 2.93. Caliway Biopharmaceuticals Co's value of 16.02 is 447.7% above this benchmark. Historically, Caliway Biopharmaceuticals Co's own PB Ratio has ranged from 4.80 to 42.09 over the past decade. While the company's 10-year median is 17.64 vs. the industry median of 2.93, Caliway Biopharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.93, based on 1,216 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Caliway Biopharmaceuticals Co's current PB Ratio of 16.02 is 447.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Caliway Biopharmaceuticals Co and its competitors. For the Biotechnology industry, the median PB Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Caliway Biopharmaceuticals Co's current PB Ratio is 16.02, which is near median its own 10-year median of 17.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caliway Biopharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Caliway Biopharmaceuticals Co (TPE:6919) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$59.00, compared to a current price of NT$94.80 — trading 60.7% above its estimated fair value. The current PB Ratio is 16.02, which is near median its 10-year median of 17.64 and 447.7% above the Biotechnology industry median of 2.93. Caliway Biopharmaceuticals Co's overall GF Score™ is 55/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Caliway Biopharmaceuticals Co (TPE:6919), the current PB Ratio is 16.02 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Caliway Biopharmaceuticals Co (TPE:6919) Overvalued in 2026?
Based on GuruFocus' analysis, Caliway Biopharmaceuticals Co stock appears to be overvalued.
The current stock price of NT$94.80 is trading 60.7% above its estimated GF Value™ of NT$59.00.
GuruFocus considers Caliway Biopharmaceuticals Co to be Significantly Overvalued.
Key valuation signals for TPE:6919:
PB Ratio: 16.02 (near median its 10-year median of 17.64)
GF Value™: NT$59.00 vs. price of NT$94.80 (60.7% above fair value)
Industry Position: 447.7% above the Biotechnology median (#1119 of 1216)
No single metric tells the full story. See the TPE:6919 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Caliway Biopharmaceuticals Co Ltd specializes in the development of new drugs for aesthetic medicine and chronic inflammation. The group has one operating segment, which is Healthy Food, and others.
55GF Score
Get the complete analysis for TPE:6919
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6919 has been successfully added to your 
